These results indicate that proTAME-containing therapies significantly inhibit MMP2 and MMP9 expression, particularly in RT4 bladder cancer cells, suggesting its potential to selectively modulate key pathways involved in tumor invasion and metastasis. This evidence concerns the gene MMP2 and urinary bladder cancer.